KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Amneal Pharmaceuticals (AMRX) Deferred Taxes (2017 - 2019)

Amneal Pharmaceuticals has reported Deferred Taxes over the past 3 years, most recently at $33000.0 for Q4 2019.

For Q4 2019, Deferred Taxes rose 110.06% year-over-year to $33000.0; the TTM value through Sep 2020 reached $33000.0, down 99.99%, while the annual FY2019 figure was $371.7 million, 4038.09% up from the prior year.
Deferred Taxes for Q4 2019 was $33000.0 at Amneal Pharmaceuticals, down from $389.9 million in the prior quarter.
Over five years, Deferred Taxes peaked at $389.9 million in Q3 2019 and troughed at -$14.5 million in Q2 2018.
A 3-year average of $36.3 million and a median of -$420000.0 in 2018 define the central range for Deferred Taxes.
On a YoY basis, Deferred Taxes climbed as much as 6528.56% in 2019 and fell as far as 1830.47% in 2019.
Year by year, Deferred Taxes stood at $1.3 million in 2017, then tumbled by 125.71% to -$328000.0 in 2018, then skyrocketed by 110.06% to $33000.0 in 2019.
Business Quant data shows Deferred Taxes for AMRX at $33000.0 in Q4 2019, $389.9 million in Q3 2019, and -$8.3 million in Q2 2019.